| |
JERSEY
CITY, N.J. (February 26, 2008):
Lux Biosciences, Inc., a privately held biotechnology company specialized in
the field of ophthalmic diseases, announced today the online publication of
abstracts for presentations by the company and its collaborators concerning
the development of the company’s lead phase 3 products LX211 and LX201, as
well as two earlier stage projects. The presentations will be part of the
upcoming ARVO 2008 Annual Meeting, “Eyes on Innovation,” to be held April 27
– May 1, 2008 in Fort Lauderdale, FL. Access to the published abstracts is
available on the ARVO website at
http://www.arvo.org.
“We will be showcasing
at ARVO the depth of Lux Biosciences’ development pipeline, and we are very
pleased to report remarkable progress with all of our projects,” said Ulrich
Grau, Ph.D., Lux Biosciences President and Chief Executive Officer.
“Notably, during this meeting we have presentations on our two phase 3
clinical programs in uveitis and in cornea transplantation. We also will be
presenting highly original work with bioerodible polymers as well as a
clear, mixed micellar formulation for ocular delivery of our next generation
calcineurin inhibitor (LX212 and LX214, respectively). These latter two
product candidates are tailor-made for dry eye and other, highly prevalent
chronic inflammatory diseases of the eye.”
Lux
Biosciences’ presentations include two orally presented papers:
|
Program Number: |
1146 |
|
Abstract Title: |
Design of Phase 2/3 Clinical Trials of a Cyclosporine A Eluting
Implant, LX201, for the Prevention and Treatment of Corneal
Allograft Rejection or Graft Failure in Patients at High Risk |
|
Session Number: |
210 |
|
Session Date/Start Time: |
Monday Apr 28, 2008, 8:30 AM – 10:15 AM |
|
Presentation Start-End Time: |
8:30:00 AM – 8:45:00 AM |
|
Room: |
Floridian Ballroom BCD |
|
Program Number: |
5007 |
|
Abstract Title: |
Development of a Bioerodible Insert for the Ocular Delivery of a
Novel Next Generation Calcineurin Inhibitor |
|
Session Number: |
501 |
|
Session Date/ Start Time: |
Thursday May 1, 2008, 8:30 AM – 10:15 AM |
|
Presentation Start-End: |
9:30:00 AM – 9:45:00 AM |
|
Room: |
Room 114 |
Four poster
presentations relating to LX 211, LX201 and LX214 will also be included as
part of the ARVO meeting program:
|
Program Number: |
114 |
|
Abstract Title: |
Development and Characterization of a Clear, Mixed Micellar
Formulation of a Next-Generation Calcineurin Inhibitor, for
Treatment of Dry Eye Syndrome |
|
Session Number: |
106 |
|
Session Date/Start Time: |
Sunday Apr 27, 2008, 8:30 AM – 10:15 AM |
|
Poster Board: |
A141 |
|
Room: |
Hall B/C |
|
Program Number: |
1964 |
|
Abstract Title: |
Preclinical Acute Toxicity and Pharmacokinetics of Episcleral LX201
Implants in Rabbits |
|
Session Number: |
257 |
|
Session Date/ Start Time: |
Monday Apr 28, 2008, 11:15 AM – 1:00 PM |
|
Poster Board: |
D935 |
|
Room: |
Hall B/C |
|
Program Number: |
3883 |
|
Abstract Title: |
Design of Phase 2/3 Clinical Trials of a Novel Calcineurin
Inhibitor, LX211, for the Treatment of Non-Infectious Uveitis |
|
Session Number: |
418 |
|
Session Date/ Start Time: |
Wednesday Apr 30, 2008, 8:30 AM – 10:15 AM |
|
Poster Board: |
A503 |
|
Room: |
Hall B/C |
|
Program Number: |
4745 |
|
Abstract Title: |
LX211 (ISA247) Suppresses Anti-CD3 Activated Human T-Cell
Proliferation and Effectively Treats Experimental Autoimmune Uveitis
in Rats |
|
Session Number: |
479 |
|
Session Date/ Start Time: |
Wednesday Apr 30, 2008, 3:00 PM – 4:45 PM |
|
Poster Board: |
A551 |
|
Room: |
Hall B/C |
About Lux Biosciences
Lux Biosciences, Inc. is
a privately held biotechnology company focused on ophthalmic diseases. The
company has a staged product portfolio of potentially first-in-class
therapies distinguished by their short-term path to commercialization and
potential to generate high revenue growth. The portfolio includes:
-
Two Phase
III clinical-stage projects including: i) LX211, the oral formulation of a
next-generation calcineurin inhibitor developed as steroid sparing therapy
for the treatment of non-infectious uveitis, and ii) LX201, a silicone
matrix ocular (episcleral) implant that steadily releases therapeutic doses
of cyclosporine A locally to the eye for the prevention of rejection cornea
transplant recipients. Both the LUMINATE pivotal clinical program for LX211
for the treatment of uveitis, as well as the LUCIDA pivotal clinical program
with LX201 for the prevention of corneal transplant rejection were initiated
in early 2007 and include sites in North America and Europe.
-
LX214, a
novel topical eye drop formulation currently in IND-enabling studies with a
target date for entry into the clinic in mid 2008. LX214 is based on Lux’
proprietary next-generation calcineurin inhibitor and is targeted towards
other chronic inflammatory diseases of the eye, most notably dry eye
syndrome, blepharitis and atopic keratoconjunctivitis.
-
Several
earlier stage projects based on proprietary product-enabling bio-erodible
polymer technologies that facilitate targeted and sustained delivery of
molecules to the eye.
For more information on
Lux Biosciences, please visit the company’s website at
www.luxbio.com.
###
CONTACTS:
Lux
Biosciences, Inc.
Ulrich Grau,
Ph.D.
+1 201 946
0221
Ulrich.grau@luxbio.com
Kureczka/Martin
Associates (media)
Joan Kureczka
+1
415-821-2413
Jkureczka@comcast.net
© 2008 Lux
Biosciences, Inc. All rights reserved.
Web
Terms |
